Corporate Sponsorsview all sponsors
MSHO continuously contacts legislators, provides comments to policy makers and collaborates with payers on issues of concern to those delivering care to cancer patients.
It is important that our members are aware of meetings, web casts, and other educational opportunities specifically designed to address the complexities of cancer care.
FDA Grants Accelerated Approval to a New Dosing Regimen of 400 mg Every Six Weeks for Merck's KEYTRUDA® (pembrolizumab)Details >
Merck's Biosimilar ONTRUZANT® (trastuzumab-dttb) is Available through Specialty Distributors and WholesalersDetails >
Important safety information and full prescribing information for capsulesDetails >